BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 32327175)

  • 21. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
    Filipska M; Rosell R
    Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.
    Yao Y; Liu J; Li L; Yuan Y; Nan K; Wu X; Zhang Z; Wu Y; Li X; Zhu J; Meng X; Wei L; Chen J; Jiang Z
    Oncotarget; 2017 Jan; 8(2):2130-2140. PubMed ID: 27791985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumour DNA in
    Cabanero M; Tsao MS
    Curr Oncol; 2018 Jun; 25(Suppl 1):S38-S44. PubMed ID: 29910646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
    Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
    Koessler T; Addeo A; Nouspikel T
    Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
    Abbosh C; Frankell AM; Harrison T; Kisistok J; Garnett A; Johnson L; Veeriah S; Moreau M; Chesh A; Chaunzwa TL; Weiss J; Schroeder MR; Ward S; Grigoriadis K; Shahpurwalla A; Litchfield K; Puttick C; Biswas D; Karasaki T; Black JRM; Martínez-Ruiz C; Bakir MA; Pich O; Watkins TBK; Lim EL; Huebner A; Moore DA; Godin-Heymann N; L'Hernault A; Bye H; Odell A; Roberts P; Gomes F; Patel AJ; Manzano E; Hiley CT; Carey N; Riley J; Cook DE; Hodgson D; Stetson D; Barrett JC; Kortlever RM; Evan GI; Hackshaw A; Daber RD; Shaw JA; Aerts HJWL; Licon A; Stahl J; Jamal-Hanjani M; ; Birkbak NJ; McGranahan N; Swanton C
    Nature; 2023 Apr; 616(7957):553-562. PubMed ID: 37055640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolving role of liquid biopsy in lung cancer.
    Malapelle U; Pisapia P; Pepe F; Russo G; Buono M; Russo A; Gomez J; Khorshid O; Mack PC; Rolfo C; Troncone G
    Lung Cancer; 2022 Oct; 172():53-64. PubMed ID: 35998482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
    Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
    Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
    PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Moding EJ; Diehn M; Wakelee HA
    Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liquid biopsy for cancer screening, diagnosis, and treatment.
    Smania MA
    J Am Assoc Nurse Pract; 2020 Jan; 32(1):5-7. PubMed ID: 31913212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
    Chen K; Zhang J; Guan T; Yang F; Lou F; Chen W; Zhao M; Zhang J; Chen S; Wang J
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1123-1131.e2. PubMed ID: 28625771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.